ID

34573

Beschrijving

Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02240238

Link

https://clinicaltrials.gov/show/NCT02240238

Trefwoorden

  1. 19-01-19 19-01-19 -
  2. 28-09-20 28-09-20 -
  3. 01-10-20 01-10-20 -
Houder van rechten

see on clinicaltrials.gov

Geüploaded op

19 januari 2019

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0

Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Solid Tumors NCT02240238

Eligibility Solid Tumors NCT02240238

Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
(part 1 only) have a histologically or cytologically confirmed diagnosis of advanced solid tumor that has relapsed or is refractory to standard curative or palliative therapy or has a contraindication to standard therapy.
Beschrijving

ID.1

Datatype

boolean

(part 2 only) have histologically or cytologically confirmed diagnosis of stage iiib or iv nsclc and have received 1 or 2 lines of prior chemotherapy or targeted therapy for stage iiib or iv nsclc (second- or third-line).
Beschrijving

ID.2

Datatype

boolean

have measurable disease per response evaluation criteria in solid tumors (recist) version 1.1.
Beschrijving

ID.3

Datatype

boolean

eastern cooperative oncology group (ecog) performance status of 0 to 1
Beschrijving

ID.4

Datatype

boolean

have adequate bone marrow reserve, liver function, and renal function
Beschrijving

ID.5

Datatype

boolean

Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
have received prior platinum therapy in the past 3 months
Beschrijving

ID.6

Datatype

boolean

have received prior cisplatin and gemcitabine concomitantly within the last 6 months or are refractory to cisplatin and gemcitabine.
Beschrijving

ID.7

Datatype

boolean

unresolved toxicity from prior radiation, chemotherapy, or other targeted treatment, including investigational treatment
Beschrijving

ID.8

Datatype

boolean

pregnant or breast feeding
Beschrijving

ID.9

Datatype

boolean

Similar models

Eligibility Solid Tumors NCT02240238

Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
(part 1 only) have a histologically or cytologically confirmed diagnosis of advanced solid tumor that has relapsed or is refractory to standard curative or palliative therapy or has a contraindication to standard therapy.
boolean
ID.2
Item
(part 2 only) have histologically or cytologically confirmed diagnosis of stage iiib or iv nsclc and have received 1 or 2 lines of prior chemotherapy or targeted therapy for stage iiib or iv nsclc (second- or third-line).
boolean
ID.3
Item
have measurable disease per response evaluation criteria in solid tumors (recist) version 1.1.
boolean
ID.4
Item
eastern cooperative oncology group (ecog) performance status of 0 to 1
boolean
ID.5
Item
have adequate bone marrow reserve, liver function, and renal function
boolean
Item Group
C0680251 (UMLS CUI)
ID.6
Item
have received prior platinum therapy in the past 3 months
boolean
ID.7
Item
have received prior cisplatin and gemcitabine concomitantly within the last 6 months or are refractory to cisplatin and gemcitabine.
boolean
ID.8
Item
unresolved toxicity from prior radiation, chemotherapy, or other targeted treatment, including investigational treatment
boolean
ID.9
Item
pregnant or breast feeding
boolean

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial